文献速递冠心病血脂与心血管预防

急性冠脉综合征PCI后非罪犯病变心肌梗死事件分析

Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome.
PubMed 文献 · J Am Coll Cardiol · 2020-01-01

基于TRITON-TIMI 38研究,12,844例ACS患者接受至少1枚支架,中位随访14.5个月。30天内事件以操作性为主(69.0%),30天后以自发性事件为主(81.8%);普拉格雷显著降低支架血栓相关和自发性心肌梗死或心血管死亡,自发性大出血增加。

要点

  • ACS患者PCI后30天内事件以操作性为主,30天后以自发性事件为主。
  • 普拉格雷显著降低支架血栓相关和自发性心肌梗死或心血管死亡。
  • 长期强化抗血小板治疗可减少新生动脉粥样血栓事件。

核心结论

  • 长期强化抗血栓治疗在预防ACS后罪犯病变支架相关并发症之外,还能减少新生(自发性)动脉粥样血栓事件。
  • ACS患者PCI后30天后自发性事件占主导,强化双联抗血小板治疗的后期心血管获益主要由减少新生动脉粥样血栓缺血事件驱动。

研究设计与样本

  • TRITON-TIMI 38研究将患者随机分配至普拉格雷或氯吡格雷,12,844例ACS患者接受至少1枚支架。
  • 中位随访14.5个月,心肌梗死和心血管死亡分为操作性、明确或 probable 支架血栓、自发性三类。

主要发现

  • 30天内首次事件中,584例(69.0%)为操作性,126例(14.9%)为支架血栓相关,136例(16.1%)为自发性。
  • 30天后事件中,22例(4.7%)为操作性,63例(13.5%)为支架血栓相关,383例(81.8%)为自发性。
  • 普拉格雷显著降低支架血栓相关事件(1.0% vs. 2.1%;p < 0.001)和自发性事件(3.9% vs. 4.8%;p = 0.012)。
  • 操作性事件方向一致但未达统计学显著(4.4% vs. 5.1%;p = 0.078)。
  • 普拉格雷增加自发性大出血,但不增加操作性大出血。

临床怎么用

  • ACS患者PCI后长期强化抗血小板治疗需兼顾减少自发性缺血事件与自发性出血风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent emphasis on reduced duration and/or intensity of antiplatelet therapy following percutaneous coronary intervention (PCI) irrespective of indication for PCI may fail to account for the substantial risk of subsequent nontarget lesion events in acute coronary syndrome (ACS) patients. OBJECTIVES: The authors sought to examine the effect of more potent antiplatelet therapy on the basis of the timing and etiology of recurrent myocardial infarction (MI) or cardiovascular death following PCI for ACS. METHODS: In the TRITON-TIMI 38 study (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38), which randomized patients to prasugrel or clopidogrel, 12,844 patients with ACS received at least 1 stent. MI and cardiovascular death were categorized as: 1) procedural (related to revascularization); 2) definite or probable stent thrombosis (ST); or 3) spontaneous (non-ST or non-procedure-related). Median follow-up was 14.5 months. RESULTS: Among the first events occurring within 30 days, 584 (69.0%) were procedural, 126 (14.9%) ST-related, and 136 (16.1%) spontaneous. After 30 days, 22 (4.7%) were procedural, 63 (13.5%) were ST-related, and 383 (81.8%) spontaneous. Prasugrel significantly reduced the incidence of MI or cardiovascular death for ST-related (1.0% vs. 2.1%; p < 0.001) and spontaneous events (3.9% vs. 4.8%; p = 0.012), with a directionally consistent numerical reduction for procedural events (4.4% vs. 5.1%; p = 0.078). Prasugrel increased spontaneous, but not procedural, major bleeding. CONCLUSIONS: Long-term potent antithrombotic therapy reduces de novo (spontaneous) atherothrombotic events in addition to preventing complications associated with stenting of the culprit lesion following ACS. In patients undergoing PCI for ACS, spontaneous events predominate after 30 days, with the later-phase cardiovascular benefit of potent dual antiplatelet therapy driven largely by reducing de novo atherothrombotic ischemic events. (Comparison of Prasugrel [CS-747] and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention; NCT00097591).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Scirica BM, Bergmark BA, Morrow DA, et al. Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome. J Am Coll Cardiol. 2020. PMID: 32164882. doi:10.1016/j.jacc.2019.12.067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。